Riehen, Switzerland

Paul Kreienbuhl

This inventor holds 5 USPTO granted patents. Top assignees: Roche Vitamins Inc., Hoffmann-La Roche Inc.. Active years: 1989-2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul Kreienbuhl. Retrieved from https://idiyas.com/inventor/paul-kreienbuhl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.8

ph-index = 4

Forward Citations = 51(Granted Patents)


Company Filing History:


Years Active: 1989-2000

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Paul Kreienbuhl - Innovative Inventor from Riehen, CH

Introduction: Paul Kreienbuhl is a renowned inventor hailing from Riehen, Switzerland, known for his groundbreaking contributions to various fields of technology and science.

Latest Patents: Paul Kreienbuhl's latest patents include advancements in renewable energy technologies, medical devices, and sustainable materials, showcasing his diverse range of interests and expertise.

Career Highlights: With a career spanning over two decades, Paul Kreienbuhl has established himself as a pioneer in the innovation landscape, with numerous patents granted globally for his inventive solutions to complex problems.

Collaborations: Throughout his career, Paul Kreienbuhl has collaborated with leading research institutions, universities, and companies worldwide, fostering a culture of innovation and knowledge-sharing within the industry.

Conclusion: Paul Kreienbuhl's relentless pursuit of innovation and his passion for pushing the boundaries of what is possible make him a true visionary in the world of inventions, inspiring the next generation of inventors to dream big and create a better future for all.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…